Pityriasis rosea during etanercept therapy

Area of Science:

• Immunodermatology
• Pharmacology
• Clinical Dermatology

Background:

• Bioengineered agents targeting the immune system offer therapeutic options for dermatologic diseases.
• Adverse cutaneous reactions are potential side effects of novel immunomodulatory therapies.
• Anti-tumor necrosis factor-alpha (anti-TNFα) drugs represent a significant advancement in treating inflammatory skin conditions.

Observation:

• Two patients developed Gibert's pityriasis rosea (PR) during treatment with etanercept.
• Etanercept is a biologic agent that inhibits tumor necrosis factor-alpha.
• The onset of PR occurred while patients were undergoing etanercept therapy for dermatologic conditions.

Findings:

• This report presents the first documented cases of Gibert's pityriasis rosea associated with etanercept therapy.
• The findings suggest a possible etiological link between anti-TNFα therapy and the development of pityriasis rosea.
• The exact mechanism underlying this association remains to be elucidated.

Implications:

• These cases highlight the importance of recognizing potential adverse cutaneous reactions to biologic therapies.
• Further research is warranted to understand the relationship between anti-TNFα agents and pityriasis rosea.
• Clinicians should consider the possibility of drug-induced pityriasis rosea in patients receiving etanercept or similar agents.